

# Charles S Cleeland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3094669/publications.pdf>

Version: 2024-02-01

211  
papers

25,110  
citations

14655

66  
h-index

6996

154  
g-index

216  
all docs

216  
docs citations

216  
times ranked

21269  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Breast Cancer Survivors With High Symptom Burden. <i>Cancer Nursing</i> , 2022, 45, 253-261.	1.5	7
2	Shortness of Breath on Day 1 After Surgery Alerting the Presence of Early Respiratory Complications After Surgery in Lung Cancer Patients. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 709-722.	1.8	3
3	Establishment of Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery After Video-Assisted Thoracoscopic Surgery. <i>Annals of Surgical Oncology</i> , 2022, 29, 5593-5604.	1.5	6
4	Symptom burden and its functional impact in patients with "asymptomatic" relapsed or refractory multiple myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 467-475.	2.2	15
5	Preferences of Individuals With Cancer for Patient-Reported Outcome Measures. <i>Oncology Nursing Forum</i> , 2021, 48, 173-183.	1.2	2
6	Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery. <i>Gynecologic Oncology</i> , 2021, 161, 83-88.	1.4	7
7	Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. <i>Supportive Care in Cancer</i> , 2021, 29, 6099-6107.	2.2	3
8	Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep. <i>European Journal of Oncology Nursing</i> , 2021, 52, 101959.	2.1	5
9	Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. <i>Neuro-Oncology Practice</i> , 2021, 8, 137-147.	1.6	3
10	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. <i>Supportive Care in Cancer</i> , 2020, 28, 261-269.	2.2	12
11	Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients. <i>Supportive Care in Cancer</i> , 2020, 28, 1809-1816.	2.2	2
12	Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 100-107.	0.8	15
13	Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. <i>Investigational New Drugs</i> , 2020, 38, 1166-1174.	2.6	1
14	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.		11
15	Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy. <i>JCO Oncology Practice</i> , 2020, 16, e893-e901.	2.9	5
16	What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e1151-e1160.	2.9	8
17	A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 1052-1058.e1.	1.2	5
18	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 787-793.	1.3	6

#	ARTICLE	IF	CITATIONS
19	The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 15.	1.9	5
20	Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). <i>Supportive Care in Cancer</i> , 2019, 27, 1021-1028.	2.2	8
21	Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 662-671.	1.2	17
22	Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 34.	1.9	6
23	Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study. <i>Supportive Care in Cancer</i> , 2019, 27, 3439-3447.	2.2	38
24	Improving attribution of adverse events in oncology clinical trials. <i>Cancer Treatment Reviews</i> , 2019, 76, 33-40.	7.7	19
25	Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). <i>Gynecologic Oncology</i> , 2019, 152, 492-500.	1.4	12
26	Interpreting Patient-reported Outcome Scores for Clinical Research and Practice. <i>Medical Care</i> , 2019, 57, S8-S12.	2.4	18
27	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10348.	4.3	13
28	Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 977-1007.	4.9	298
29	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. <i>Quality of Life Research</i> , 2018, 27, 979-985.	3.1	5
30	Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. <i>Quality of Life Research</i> , 2018, 27, 1563-1570.	3.1	12
31	Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. <i>Value in Health</i> , 2018, 21, 742-747.	0.3	79
32	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	2.1	5
33	Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). <i>Quality of Life Research</i> , 2018, 27, 3229-3241.	3.1	11
34	Removal and insertion of central venous catheters in cancer patients is associated with high symptom burden. <i>Expert Review of Medical Devices</i> , 2018, 15, 591-596.	2.8	5
35	Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. <i>JMIR Human Factors</i> , 2018, 5, e10070.	2.0	20
36	Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e67-e74.	4.6	18

#	ARTICLE	IF	CITATIONS
37	Validation of the Persian Version of the Brief Pain Inventory (BPI-P) in Chronic Pain Patients. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 132-138.e2.	1.2	35
38	Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. <i>Clinical Trials</i> , 2017, 14, 255-263.	1.6	58
39	An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. <i>Quality of Life Research</i> , 2017, 26, 2067-2078.	3.1	27
40	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. <i>Radiation Oncology</i> , 2017, 12, 150.	2.7	25
41	Enhancing quality of life as a goal for anticancer therapeutics. <i>Science Translational Medicine</i> , 2016, 8, 344ed9.	12.4	5
42	Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 3557-3565.	2.2	32
43	Psychometric Validation of the M. D. Anderson Symptom Inventory's Head and Neck Module in the Spanish Language. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 1055-1061.	1.2	9
44	Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 832-838.	1.2	27
45	Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. <i>Oncology</i> , 2016, 90, 127-135.	1.9	25
46	Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 822-831.	1.2	36
47	Validity and Reliability of the Indonesian Version of the Brief Fatigue Inventory in Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 744-751.	1.2	20
48	Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. <i>European Journal of Cancer</i> , 2016, 67, 83-90.	2.8	16
49	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. <i>Cancer</i> , 2016, 122, 3401-3409.	4.1	50
50	Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. <i>Cancer</i> , 2016, 122, 438-446.	4.1	35
51	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1107-1114.	0.8	121
52	Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. <i>Supportive Care in Cancer</i> , 2016, 24, 1327-1337.	2.2	61
53	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 226-231.	2.0	15
54	Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module. <i>Balkan Medical Journal</i> , 2016, 33, 339-343.	0.8	2

#	ARTICLE	IF	CITATIONS
55	The symptom burden of treatment-naïve patients with head and neck cancer. <i>Cancer</i> , 2015, 121, 766-773.	4.1	56
56	Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. <i>Journal of Pain</i> , 2015, 16, 1032-1043.	1.4	23
57	Automated pain intervention for underserved minority women with breast cancer. <i>Cancer</i> , 2015, 121, 1882-1890.	4.1	27
58	Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. <i>Supportive Care in Cancer</i> , 2015, 23, 1157-1168.	2.2	31
59	Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>JAMA Oncology</i> , 2015, 1, 1051.	7.1	581
60	Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1335-1341.	1.3	29
61	Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. <i>Thyroid</i> , 2015, 25, 1085-1090.	4.5	22
62	Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 613-619.e2.	0.8	92
63	Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. <i>Cancer</i> , 2015, 121, 1138-1146.	4.1	23
64	Symptom Burden of Cancer Patients: Validation of the German M. D. Anderson Symptom Inventory: A Cross-Sectional Multicenter Study. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 117-125.	1.2	15
65	A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2015, 126, 2094-2094.	1.4	8
66	Screening for Depressed Mood in Patients With Cancer Using the MD Anderson Symptom Inventory: Investigation of a Practical Approach for the Oncologist. <i>Journal of Oncology Practice</i> , 2014, 10, e95-e102.	2.5	12
67	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the National Cancer Institute</i> , 2014, 106, dju244-dju244.	6.3	689
68	Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. <i>Breast</i> , 2014, 23, 763-769.	2.2	50
69	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. <i>Cancer</i> , 2014, 120, 1975-1984.	4.1	106
70	Predictors of significant worsening of patient-reported fatigue over a 1-month timeframe in ambulatory patients with common solid tumors. <i>Cancer</i> , 2014, 120, 442-450.	4.1	17
71	A Randomized, Double-blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients. <i>Cancer Journal (Sudbury, Mass )</i> , 2014, 20, 8-14.	2.0	76
72	Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non-Small-Cell Lung Cancer: Treatment Setting and Minority Status Do Not Make a Difference. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1459-1463.	1.1	19

#	ARTICLE	IF	CITATIONS
73	Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. <i>Journal of Clinical Oncology</i> , 2014, 32, 3156-3162.	1.6	37
74	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 619-626.	1.9	18
75	The Validity and Utility of the MD Anderson Symptom Inventory in Patients With Prostate Cancer: Evidence From the Symptom Outcomes and Practice Patterns (SOAPP) Data From the Eastern Cooperative Oncology Group. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 41-49.	1.9	31
76	Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2014, 20, 1366-1374.	7.0	57
77	Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors. <i>Cancer</i> , 2014, 120, 425-432.	4.1	259
78	Symptom burden in hematologic malignancies. <i>Blood</i> , 2014, 123, 3686-3687.	1.4	13
79	High symptom burden prior to radiation therapy for head and neck cancer: A patient-reported outcomes study. <i>Head and Neck</i> , 2013, 35, 1490-1498.	2.0	48
80	Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. <i>Journal of Hematology and Oncology</i> , 2013, 6, 13.	17.0	42
81	Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. <i>Quality of Life Research</i> , 2013, 22, 2331-2339.	3.1	38
82	Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer. <i>Quality of Life Research</i> , 2013, 22, 2143-2150.	3.1	21
83	Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1531-1540.	2.3	15
84	Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance. <i>Drug Safety</i> , 2013, 36, 1129-1149.	3.2	84
85	Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. <i>Supportive Care in Cancer</i> , 2013, 21, 3497-3507.	2.2	80
86	The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. <i>Cancer</i> , 2013, 119, 4333-4340.	4.1	235
87	Mechanisms of treatment-related symptoms in cancer patients. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 301-302.	2.2	3
88	Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 130, 323-328.	1.4	60
89	The Validity and Utility of the M. D. Anderson Symptom Inventory in Patients With Breast Cancer: Evidence From the Symptom Outcomes and Practice Patterns Data From the Eastern Cooperative Oncology Group. <i>Clinical Breast Cancer</i> , 2013, 13, 325-334.	2.4	33
90	Anastrozole-Associated Joint Pain and Other Symptoms in Patients With Breast Cancer. <i>Journal of Pain</i> , 2013, 14, 290-296.	1.4	27

#	ARTICLE	IF	CITATIONS
91	Capturing the Patient's Experience: Using Qualitative Methods to Develop a Measure of Patient-Reported Symptom Burden: An Example From Ovarian Cancer. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 837-845.	1.2	20
92	Recommendations for including multiple symptoms as endpoints in cancer clinical trials. <i>Cancer</i> , 2013, 119, 411-420.	4.1	46
93	Pain outcomes in patients with advanced breast cancer and bone metastases. <i>Cancer</i> , 2013, 119, 832-838.	4.1	126
94	Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. <i>Clinical Investigation</i> , 2013, 3, 1127-1138.	0.0	3
95	Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. <i>Cancer</i> , 2013, 119, 4188-4195.	4.1	53
96	Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. <i>Blood</i> , 2013, 122, 641-647.	1.4	91
97	Adult Cancer Pain. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 992-1022.	4.9	144
98	A new symptom measure in gastrointestinal stomal tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17508-e17508.	1.6	1
99	Prospective, Observational Study of Pain and Analgesic Prescribing in Medical Oncology Outpatients With Breast, Colorectal, Lung, or Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1980-1988.	1.6	244
100	Cancer- and Chemotherapy-Induced Anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 628-653.	4.9	153
101	Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1â€“2 trial. <i>Lancet Oncology, The</i> , 2012, 13, 395-402.	10.7	289
102	Symptoms and Quality of Life in Diverse Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 168-180.	1.2	99
103	Changes in Pain and Other Symptoms in Patients With Painful Multiple Myeloma-Related Vertebral Fracture Treated With Kyphoplasty or Vertebroplasty. <i>Journal of Pain</i> , 2012, 13, 564-570.	1.4	37
104	Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 699-705.	4.1	94
105	Reducing the toxicity of cancer therapy: recognizing needs, taking action. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 471-478.	27.6	102
106	Congruence of primary brain tumor patient and caregiver symptom report. <i>Cancer</i> , 2012, 118, 5026-5037.	4.1	27
107	Translational approaches to treatment-induced symptoms in cancer patients. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 414-426.	27.6	115
108	Linguistic validation of the Greek M.D. Anderson Symptom Inventory - Head and Neck Module. , 2012, 3, 29-31.		2



#	ARTICLE	IF	CITATIONS
109	Caregiver symptom burden: The risk of caring for an underserved patient with advanced cancer. <i>Cancer</i> , 2011, 117, 1070-1079.	4.1	102
110	The impact of symptom interference using the MD Anderson Symptom Inventory's Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. <i>Cancer</i> , 2011, 117, 3222-3228.	4.1	35
111	Symptom burden in cancer survivors 1 year after diagnosis. <i>Cancer</i> , 2011, 117, 2779-2790.	4.1	226
112	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 587-599.	1.4	12
113	Levels of Symptom Burden During Chemotherapy for Advanced Lung Cancer: Differences Between Public Hospitals and a Tertiary Cancer Center. <i>Journal of Clinical Oncology</i> , 2011, 29, 2859-2865.	1.6	37
114	Measuring the Symptom Burden of Lung Cancer: The Validity and Utility of the Lung Cancer Module of the M. D. Anderson Symptom Inventory. <i>Oncologist</i> , 2011, 16, 217-227.	3.7	99
115	Integrating Pain Metrics into Oncology Clinical Trials. <i>Clinical Cancer Research</i> , 2011, 17, 6646-6650.	7.0	15
116	Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1851-1858.	6.3	196
117	Automated Symptom Alerts Reduce Postoperative Symptom Severity After Cancer Surgery: A Randomized Controlled Clinical Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 994-1000.	1.6	280
118	Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 137-145.	4.1	61
119	Biological pathways and genetic variables involved in pain. <i>Quality of Life Research</i> , 2010, 19, 1407-1417.	3.1	33
120	Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): Searching for Standards. <i>Journal of Pain and Symptom Management</i> , 2010, 39, 1077-1085.	1.2	77
121	Cancer-Related Symptom Assessment in France: Validation of the French M. D. Anderson Symptom Inventory. <i>Journal of Pain and Symptom Management</i> , 2010, 39, 721-733.	1.2	34
122	Validation and Application of the Arabic Version of the M. D. Anderson Symptom Inventory in Moroccan Patients With Cancer. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 75-86.	1.2	29
123	Does Recall Period Have an Effect on Cancer Patients' Ratings of the Severity of Multiple Symptoms?. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 191-199.	1.2	27
124	ASCPRO Recommendations for the Assessment of Fatigue as an Outcome in Clinical Trials. <i>Journal of Pain and Symptom Management</i> , 2010, 39, 1086-1099.	1.2	112
125	Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). <i>Cancer</i> , 2010, 116, 2053-2063.	4.1	79
126	Impact of Cultural and Linguistic Factors on Symptom Reporting by Patients With Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 732-738.	6.3	44



#	ARTICLE	IF	CITATIONS
127	Assessment of Cancer-Related Neuropathy and Neuropathic Pain. <i>Oncologist</i> , 2010, 15, 13-18.	3.7	50
128	Assessment of Fatigue in Cancer Patients and Community Dwellers: Validation Study of the Filipino Version of the Brief Fatigue Inventory. <i>Oncology</i> , 2010, 79, 112-117.	1.9	26
129	Reliability and validity of the M. D. Anderson Symptom Inventoryâ€™Spine Tumor Module. <i>Journal of Neurosurgery: Spine</i> , 2010, 12, 421-430.	1.7	36
130	Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 968-974.	4.1	150
131	Developing translational animal models of cancer-related fatigue. , 2010, , 124-141.		3
132	Symptom measurement by patient report. , 2010, , 268-284.		2
133	The Establishment of the GENEQOL Consortium to Investigate the Genetic Disposition of Patient-Reported Quality-of-Life Outcomes. <i>Twin Research and Human Genetics</i> , 2009, 12, 301-311.	0.6	48
134	Development and Initial Validation of the Thyroid Cancer Module of the M. D. Anderson Symptom Inventory. <i>Oncology</i> , 2009, 76, 59-68.	1.9	46
135	Clinical Utility of the MDASI-BT in Patients with Brain Metastases. <i>Journal of Pain and Symptom Management</i> , 2009, 37, 331-340.	1.2	38
136	Temporal Patterns of Fatigue Predict Pathologic Response in Patients Treated With Preoperative Chemoradiation Therapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 775-781.	0.8	22
137	Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. <i>Lancet Oncology</i> , The, 2009, 10, 865-871.	10.7	519
138	Symptom burden after autologous stem cell transplantation for multiple myeloma. <i>Cancer</i> , 2008, 112, 1617-1624.	4.1	40
139	Serum interleukinâ€™6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. <i>Cancer</i> , 2008, 113, 2102-2109.	4.1	71
140	The M. D. Anderson Symptom Inventoryâ€™Head and Neck Module, a Patient-Reported Outcome Instrument, Accurately Predicts the Severity of Radiation-Induced Mucositis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1355-1361.	0.8	72
141	Pain and Suffering During Cancer Therapy: Continued Sins of Omission. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 6-8.	0.8	15
142	Psychometric Properties of the Brief Fatigue Inventory in Greek Patients with Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2008, 36, 367-373.	1.2	21
143	Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations. <i>Journal of Pain</i> , 2008, 9, 105-121.	1.4	2,564
144	Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. <i>Pain</i> , 2008, 139, 485-493.	4.2	179

#	ARTICLE	IF	CITATIONS
145	Psychometric Testing of the MDASI-HF: A Symptom Assessment Instrument for Patients With Cancer and Concurrent Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 497-507.	1.7	37
146	Health Care Providers' Assessments of the Quality of Advanced-Cancer Care in Latin American Medical Institutions: A Comparison of Predictors in Five Countries: Argentina, Brazil, Cuba, Mexico, and Peru. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2008, 22, 7-20.	0.8	14
147	Assessing Cancer Symptoms in Adolescents With Cancer Using the Taiwanese Version of the M. D. Anderson Symptom Inventory. <i>Cancer Nursing</i> , 2008, 31, E9-E16.	1.5	26
148	Symptom Burden: Multiple Symptoms and Their Impact as Patient-Reported Outcomes. <i>Journal of the National Cancer Institute Monographs</i> , 2007, 2007, 16-21.	2.1	341
149	Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. <i>Head and Neck</i> , 2007, 29, 923-931.	2.0	227
150	Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia. <i>Cancer</i> , 2007, 110, 1629-1640.	4.1	30
151	Patient-Reported Outcomes: Instrument Development and Selection Issues. <i>Value in Health</i> , 2007, 10, S86-S93.	0.3	122
152	Taiwanese Version of the M. D. Anderson Symptom Inventory: Symptom Assessment in Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2007, 33, 180-188.	1.2	75
153	Assessment of clinical relevant fatigue level in cancer. <i>Supportive Care in Cancer</i> , 2007, 15, 891-896.	2.2	53
154	Symptom burden in cancer survivorship. <i>Journal of Cancer Survivorship</i> , 2007, 1, 167-175.	2.9	68
155	Asking the Community About Cutpoints Used to Describe Mild, Moderate, and Severe Pain. <i>Journal of Pain</i> , 2006, 7, 49-56.	1.4	102
156	The Association between Symptom Burdens and Utility in Chinese Cancer Patients. <i>Quality of Life Research</i> , 2006, 15, 1427-1438.	3.1	11
157	Validation Study of the Korean Version of the M. D. Anderson Symptom Inventory. <i>Journal of Pain and Symptom Management</i> , 2006, 31, 345-352.	1.2	64
158	Filipino Version of the M. D. Anderson Symptom Inventory: Validation and Multisymptom Measurement in Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2006, 31, 542-552.	1.2	41
159	Pain, Depression, and Fatigue in Community-Dwelling Adults With and Without a History of Cancer. <i>Journal of Pain and Symptom Management</i> , 2006, 32, 118-128.	1.2	105
160	Brief cognitive-behavioral audiotape interventions for cancer-related pain. <i>Cancer</i> , 2006, 107, 207-214.	4.1	52
161	Longitudinal Study of the Relationship Between Chemoradiation Therapy for Non-Small-Cell Lung Cancer and Patient Symptoms. <i>Journal of Clinical Oncology</i> , 2006, 24, 4485-4491.	1.6	108
162	The Measurement of Pain from Metastatic Bone Disease: Capturing the Patient's Experience. <i>Clinical Cancer Research</i> , 2006, 12, 6236s-6242s.	7.0	100

#	ARTICLE	IF	CITATIONS
163	Cancer-Related Symptom Assessment in Russia: Validation and Utility of the Russian M. D. Anderson Symptom Inventory. <i>Journal of Pain and Symptom Management</i> , 2005, 30, 443-453.	1.2	49
164	Content Validity of Self-Report Measurement Instruments: An Illustration From the Development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. <i>Oncology Nursing Forum</i> , 2005, 32, 669-676.	1.2	66
165	Epidemiology of Pain and Cancer-Related Symptoms. , 2005, , 1029-1037.		1
166	Symptom Assessment. , 2005, , 991-1004.		0
167	A Cytokine-Based Neuroimmunologic Mechanism of Cancer-Related Symptoms. <i>NeuroImmunoModulation</i> , 2004, 11, 279-292.	1.8	266
168	Adequacy of Cancer Pain Management in a Japanese Cancer Hospital. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 37-42.	1.3	58
169	Greek M.D. Anderson Symptom Inventory: Validation and Utility in Cancer Patients. <i>Oncology</i> , 2004, 67, 203-210.	1.9	49
170	Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-C). <i>Journal of Pain and Symptom Management</i> , 2004, 27, 322-332.	1.2	84
171	Chinese version of the M. D. Anderson Symptom Inventory. <i>Cancer</i> , 2004, 101, 1890-1901.	4.1	165
172	The analgesic effects that underlie patient satisfaction with treatment. <i>Pain</i> , 2004, 110, 480-487.	4.2	28
173	Pediatric Cancer Pain Management Practices and Attitudes in China. <i>Journal of Pain and Symptom Management</i> , 2003, 26, 748-759.	1.2	22
174	Japanese version of the M.D. Anderson Symptom Inventory: A validation study. <i>Journal of Pain and Symptom Management</i> , 2003, 26, 1093-1104.	1.2	127
175	Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?. <i>Cancer</i> , 2003, 97, 2919-2925.	4.1	460
176	Pain and Fatigue in Community-Dwelling Adults. <i>Pain Medicine</i> , 2003, 4, 231-237.	1.9	29
177	Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. <i>Pain</i> , 2003, 106, 337-345.	4.2	1,850
178	Rapid Improvement in Pain Management: The Veterans Health Administration and the Institute for Healthcare Improvement Collaborative. <i>Clinical Journal of Pain</i> , 2003, 19, 298-305.	1.9	73
179	Impact of pain on self-rated health in the community-dwelling older adults. <i>Pain</i> , 2002, 95, 75-82.	4.2	211
180	Cancer pain management among underserved minority outpatients. <i>Cancer</i> , 2002, 94, 2295-2304.	4.1	226

#	ARTICLE	IF	CITATIONS
181	Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. <i>Cancer</i> , 2002, 95, 888-895.	4.1	398
182	When is it justified to treat symptoms? Measuring symptom burden. <i>Oncology</i> , 2002, 16, 64-70.	0.5	37
183	Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing. <i>Journal of Clinical Oncology</i> , 2001, 19, 2875-2882.	1.6	574
184	Introduction. <i>Cancer</i> , 2001, 92, 1657-1661.	4.1	16
185	A fatigue clinic in a comprehensive cancer center. <i>Cancer</i> , 2001, 92, 1708-1713.	4.1	26
186	Cancer Pain: Progress Since the WHO Guidelines. <i>Pain Practice</i> , 2001, 1, 236-242.	1.9	15
187	A Preliminary Study of the Utility of the Brief Hospice Inventory. <i>Journal of Pain and Symptom Management</i> , 2001, 22, 637-648.	1.2	31
188	Cancer Pain: Progress Since the WHO Guidelines. <i>Pain Practice</i> , 2001, 1, 236-242.	1.9	13
189	Assessing symptom distress in cancer patients. <i>Cancer</i> , 2000, 89, 1634-1646.	4.1	1,156
190	Cancer pain management by radiotherapists: a survey of radiation therapy oncology group physicians. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 203-208.	0.8	83
191	Cancer-related symptoms. <i>Seminars in Radiation Oncology</i> , 2000, 10, 175-190.	2.2	128
192	The rapid assessment of fatigue severity in cancer patients. <i>Cancer</i> , 1999, 85, 1186-1196.	4.1	1,482
193	The effects of pain severity on health-related quality of life. <i>Cancer</i> , 1999, 86, 1848-1855.	4.1	104
194	World conference for cancer organisations march 3-7, 1996, melbourne, australia. <i>Cancer</i> , 1998, 82, 234-234.	4.1	0
195	Undertreatment of Cancer Pain in Elderly Patients. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1914.	7.4	127
196	Pain and Treatment of Pain in Minority Patients with Cancer: The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. <i>Annals of Internal Medicine</i> , 1997, 127, 813.	3.9	472
197	Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. <i>Pain</i> , 1996, 67, 267-273.	4.2	219
198	When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. <i>Pain</i> , 1995, 61, 277-284.	4.2	1,265

#	ARTICLE	IF	CITATIONS
199	Pain and Its Treatment in Outpatients with Metastatic Cancer. <i>New England Journal of Medicine</i> , 1994, 330, 592-596.	27.0	1,920
200	Factors influencing physician management of cancer pain. <i>Cancer</i> , 1986, 58, 796-800.	4.1	159
201	Public attitudes toward cancer pain. <i>Cancer</i> , 1985, 56, 2337-2339.	4.1	184
202	The Behavior of Normal and Stomach Lesion Susceptible Rats in Several Learning Situations. <i>Journal of Genetic Psychology</i> , 1963, 102, 91-94.	1.2	19
203	Introduction to cancer symptom science. , 0, , 1-3.		1
204	Cytokines and sickness behavior: a model for cancer symptoms. , 0, , 8-17.		0
205	From inflammation to sickness and depression: the cytokine connection. , 0, , 95-109.		0
206	Cancer-related fatigue: clinical science. , 0, , 110-123.		0
207	Genetic approaches to treating and preventing symptoms in patients with cancer. , 0, , 192-205.		0
208	High-dose therapy and posttransplantation symptom burden: striking a balance. , 0, , 224-236.		0
209	Bayesian adaptive design: a novel approach to test the effectiveness of symptom-reducing agents using patient-reported outcomes. , 0, , 293-303.		0
210	Developing symptom management drugs. , 0, , 314-324.		0
211	Symptom research: looking ahead. , 0, , 341-348.		0